ResearcherHeidelberg UniversityActive in the last 2 years

Bo Kong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-4997-8009; OpenAlex author ID A5146760288. Sources: OpenAlex.

Their work

Papers: 3 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 24

Papers, trials and grants by year

2025: 1 paper · 2026: 2 papers

Papers 3

Dual mTORC1/2 and Scd1 inhibition uncovers a therapeutic vulnerability in pancreatic cancer. Last author DOI 10.1038/s41388-026-04026-x ↗
A Comprehensive Assessment of the Causal Relationship between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study. Co-author DOI 10.1158/1055-9965.epi-25-1601 ↗
ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. Last author DOI 10.1038/s41388-025-03530-w ↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Chao Fang · 2 shared papers, 2025–2026 · strength 0.38
- Paper Dual mTORC1/2 and Scd1 inhibition uncovers a therapeutic vulnerability in pancreatic cancer. DOI 10.1038/s41388-026-04026-x ↗
- Paper ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. DOI 10.1038/s41388-025-03530-w ↗
Christoph W. Michalski · 2 shared papers, 2025–2026 · strength 0.38
- Paper Dual mTORC1/2 and Scd1 inhibition uncovers a therapeutic vulnerability in pancreatic cancer. DOI 10.1038/s41388-026-04026-x ↗
- Paper ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. DOI 10.1038/s41388-025-03530-w ↗
Helmut Friess · 2 shared papers, 2025–2026 · strength 0.38
- Paper Dual mTORC1/2 and Scd1 inhibition uncovers a therapeutic vulnerability in pancreatic cancer. DOI 10.1038/s41388-026-04026-x ↗
- Paper ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. DOI 10.1038/s41388-025-03530-w ↗
Ingrid Herr · 2 shared papers, 2025–2026 · strength 0.38
- Paper Dual mTORC1/2 and Scd1 inhibition uncovers a therapeutic vulnerability in pancreatic cancer. DOI 10.1038/s41388-026-04026-x ↗
- Paper ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. DOI 10.1038/s41388-025-03530-w ↗
Thomas P. Hank · 1 shared paper, 2026 · strength 0.22
- Paper Dual mTORC1/2 and Scd1 inhibition uncovers a therapeutic vulnerability in pancreatic cancer. DOI 10.1038/s41388-026-04026-x ↗
Franco Fortunato · 1 shared paper, 2026 · strength 0.22
- Paper Dual mTORC1/2 and Scd1 inhibition uncovers a therapeutic vulnerability in pancreatic cancer. DOI 10.1038/s41388-026-04026-x ↗
Martin Loos · 1 shared paper, 2026 · strength 0.22
- Paper Dual mTORC1/2 and Scd1 inhibition uncovers a therapeutic vulnerability in pancreatic cancer. DOI 10.1038/s41388-026-04026-x ↗
Max Heckler · 1 shared paper, 2026 · strength 0.22
- Paper Dual mTORC1/2 and Scd1 inhibition uncovers a therapeutic vulnerability in pancreatic cancer. DOI 10.1038/s41388-026-04026-x ↗
İhsan Ekin Demir · 1 shared paper, 2026 · strength 0.22
- Paper Dual mTORC1/2 and Scd1 inhibition uncovers a therapeutic vulnerability in pancreatic cancer. DOI 10.1038/s41388-026-04026-x ↗
Xuetian Qian · 1 shared paper, 2025 · strength 0.16
- Paper ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. DOI 10.1038/s41388-025-03530-w ↗
Zipeng Lu · 1 shared paper, 2025 · strength 0.16
- Paper ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. DOI 10.1038/s41388-025-03530-w ↗
Yifeng Sun · 1 shared paper, 2025 · strength 0.16
- Paper ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. DOI 10.1038/s41388-025-03530-w ↗
Chao Li · 1 shared paper, 2025 · strength 0.16
- Paper ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. DOI 10.1038/s41388-025-03530-w ↗
Susanne Roth · 1 shared paper, 2025 · strength 0.16
- Paper ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. DOI 10.1038/s41388-025-03530-w ↗
Qi Zhang · 1 shared paper, 2025 · strength 0.16
- Paper ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. DOI 10.1038/s41388-025-03530-w ↗
Hongzhen Li · 1 shared paper, 2025 · strength 0.16
- Paper ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. DOI 10.1038/s41388-025-03530-w ↗
André L. Mihaljević · 1 shared paper, 2025 · strength 0.16
- Paper ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. DOI 10.1038/s41388-025-03530-w ↗
Zhiheng Zhang · 1 shared paper, 2025 · strength 0.16
- Paper ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. DOI 10.1038/s41388-025-03530-w ↗
Mingyue Hu · 1 shared paper, 2025 · strength 0.16
- Paper ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. DOI 10.1038/s41388-025-03530-w ↗
Shuang Nie · 1 shared paper, 2025 · strength 0.16
- Paper ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. DOI 10.1038/s41388-025-03530-w ↗
Jorg H. Kleeff · 1 shared paper, 2025 · strength 0.16
- Paper ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. DOI 10.1038/s41388-025-03530-w ↗
Christoph Kahlert · 1 shared paper, 2025 · strength 0.16
- Paper ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. DOI 10.1038/s41388-025-03530-w ↗
Kuirong Jiang · 1 shared paper, 2025 · strength 0.16
- Paper ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. DOI 10.1038/s41388-025-03530-w ↗
Xiaoping Zou · 1 shared paper, 2025 · strength 0.16
- Paper ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. DOI 10.1038/s41388-025-03530-w ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.